ArticleCancer causes & control : CCC2026
Evaluation of colorectal cancer screening practices in Rhode Island, 2011-2021.
Article in Cancer causes & control : CCC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sphingosine-1-phosphate induces angiogenesis via the activating STAT3 signaling pathway to drive colorectal cancer progression.Journal of gastrointestinal oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough lifestyle modifications have the potential to reduce colorectal cancer (CRC) risk, regular screening is crucial for CRC prevention. This study aimed to identify disparities in CRC screening modalities in Rhode Island (RI) adults from 2011 to 2021 to guide equitable screening practices.
methodsWe leveraged deidentified health insurance claims data from HealthFacts RI, the state's all-payer claims database. Multivariable GEE regression models were used to assess the odds of CRC screening type (i.e., CT colonography, colonoscopy, FOBT, mt-sDNA, or flexible sigmoidoscopy) and colonoscopy procedure (with or without polypectomy and/or biopsy) associated with each independent variable (i.e., sex, insurance status, age, type of screening provider, and community-level economic burden).
resultsThe analytic sample included 652,280 screenings from 2011 to 2021, of which 50.21% were attributable to females and 49.78% to males. Colonoscopies accounted for 49.93% of screenings, followed by FOBT at 45.34%. Females had over twice the odds of receiving CT colonography (OR = 2.47) but approximately 25% lower odds of receiving FOBT (OR = 0.73) compared to males. Those in economically disadvantaged communities had higher odds of receiving CT colonography (OR = 1.37), but lower odds of mt-sDNA screenings (OR = 0.71). Screenings ordered by unclassified providers had three times the odds of being FOBT (OR = 3.08) compared to other providers. These findings were all statistically significant at the 0.05 alpha level. DISCUSSION: We found discrepancies in CRC screening modalities by sex, age, insurance status, type of provider, and community-level economic burden, highlighting the need for targeted interventions to promote equitable CRC screening in Rhode Island.
Indexed as
Identifiers
41665727What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.